Drugs / Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01061658 | Jul → Nov 2010 | Rotavirus infection | Shantha Biotechnics Limited | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01061658 ↗ |
| Known as | BRV-TV | “Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine [BRV-TV] Administered to Healthy Indian Infants” NCT01061658 ↗ |
| Modality | Vaccine | “Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine” NCT01061658 ↗ |
| Route | Oral | “Three doses of the rotavirus vaccine or placebo would be administered orally to each infant at 6-8, 10-12 and 14-16 weeks of age.” NCT01061658 ↗ |